BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1502 related articles for article (PubMed ID: 19223455)

  • 21. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
    Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
    Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
    Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
    Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer.
    Cano P; Godoy A; Escamilla R; Dhir R; Onate SA
    Cancer Res; 2007 Jan; 67(2):511-9. PubMed ID: 17234758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
    Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
    Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y
    Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
    Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
    Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
    Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
    Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
    Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
    Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.
    Shiota M; Song Y; Yokomizo A; Tada Y; Kuroiwa K; Eto M; Oda Y; Inokuchi J; Uchiumi T; Fujimoto N; Seki N; Naito S
    Endocr Relat Cancer; 2010 Jun; 17(2):455-67. PubMed ID: 20308360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells.
    Gross M; Liu B; Tan J; French FS; Carey M; Shuai K
    Oncogene; 2001 Jun; 20(29):3880-7. PubMed ID: 11439351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
    Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
    Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.